Together, our results warrant further investigations to validate the potential benefits of STK25 inhibitors as an adjunctive therapy to sorafenib and regorafenib, as well as in HCC tumors that are resistant to the current first-line standard of care. Here, STK25 is linked to hepatocellular carcinoma.